A closer look: ultrastructural evaluation of high-risk progression IgA nephropathy

References

• Rovin BH, Adler SG, Barratt J. Kidney disease: improving global outcomes glomerular diseases work G. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021; 100(4):S1–S276. doi:10.1016/j.kint.2021.05.021.
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91(5):1014–1021. doi:10.1016/j.kint.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts ISD. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol. 2016;29(3):367–375. doi:10.1007/s40620-015-0227-8.
   PubMed Web of Science ®Google Scholar
• Itami S, Moriyama T, Miyabe Y, Karasawa K, Nitta K. A novel scoring system based on Oxford classification indicating steroid therapy use for IgA nephropathy. Kidney Int Rep. 2022; 7(1):99–107. doi:10.1016/j.ekir.2021.10.007.
   PubMed Web of Science ®Google Scholar
• Gu X, Herrera GA. The value of electron microscopy in the diagnosis of IgA nephropathy. Ultrastruct Pathol. 2002; 26(4):203–210. doi:10.1080/01913120290076883.
   PubMed Web of Science ®Google Scholar
• Obrisca B, Stefan G, Gherghiceanu M, et al. “Associated” or “secondary” IgA nephropathy? An outcome analysis. PLoS One. 2019;14(8):e0221014. doi: 10.1371/journal.pone.0221014.
   PubMed Web of Science ®Google Scholar
• Stefan G, Terinte-Balcan G, Stancu S, Zugravu A, Gherghiceanu M, Mircescu G. IgA nephropathy with serum ANCA positivity: case series and literature review. Rheumatol Int. 2021; 41(7):1347–1355. doi:10.1007/s00296-021-04888-2.
   PubMed Web of Science ®Google Scholar
• Steffes MW, Barbosa J, Basgen JM, Sutherland DE, Najarian JS, Mauer SM. Quantitative glomerular morphology of the normal human kidney. Lab Invest. 1983;49(1):82–86.
   PubMed Web of Science ®Google Scholar
• Sethi S, Haas M, Markowitz GS, et al. Mayo Clinic/Renal Pathology society consensus report on Pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol. 2016;27(5):1278–1287. doi:10.1681/ASN.2015060612.
   PubMed Web of Science ®Google Scholar
• Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis R. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18(12):3177–3183. doi:10.1681/ASN.2007050526.
   PubMed Web of Science ®Google Scholar
• Stefan G, Stancu S, Zugravu A, et al. Immunosuppressive therapy versus supportive care in IgA nephropathy patients with stage 3 and 4 chronic kidney disease. Medicine. 2022;101(36):e30422. doi: 10.1097/MD.0000000000030422.
   PubMed Web of Science ®Google Scholar
• Inker LA, Heerspink HJL, Tighiouart H, et al. Association of treatment effects on early change in Urine protein and treatment effects on GFR Slope in IgA nephropathy: an individual participant meta-analysis. Am J Kidney Dis. 2021;78(3):340–349 e1. doi:10.1053/j.ajkd.2021.03.007.
   PubMed Web of Science ®Google Scholar
• Canney M, Barbour SJ, Zheng Y, et al. Quantifying duration of proteinuria Remission and association with clinical outcome in IgA nephropathy. J Am Soc Nephrol. Feb 2021;32(2):436–447. doi:10.1681/ASN.2020030349.
   PubMed Web of Science ®Google Scholar
• Stefan G, Mircescu G. Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail. 2021; 43(1):1520–1527. doi:10.1080/0886022X.2021.2000875.
   PubMed Web of Science ®Google Scholar
• Thompson A, Carroll K, AI L, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469–481. doi: 10.2215/CJN.08600718.
   PubMed Web of Science ®Google Scholar
• Stefan G, Ismail G, Stancu S, et al. Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary hypercellularity and mesangial IgG immunostaining. Pathol Int. Aug 2016;66(8):453–459. doi:10.1111/pin.12442.
   PubMed Web of Science ®Google Scholar
• Choi SY, Suh KS, Choi DE, Lim BJ. Morphometric analysis of podocyte foot process effacement in IgA nephropathy and its association with proteinuria. Ultrastruct Pathol. 2010; 34(4):195–198. doi:10.3109/01913121003648402.
   PubMed Web of Science ®Google Scholar
• Lemley KV, Lafayette RA, Safai M, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int. Apr 2002;61(4):1475–1485. doi:10.1046/j.1523-1755.2002.00269.x.
   PubMed Web of Science ®Google Scholar
• Fukuda A, Sato Y, Iwakiri T, et al. Urine podocyte mRnas mark disease activity in IgA nephropathy. Nephrol Dial Transplant. 2015;30(7):1140–1150. doi:10.1093/ndt/gfv104.
   PubMed Web of Science ®Google Scholar
• Asao R, Asanuma K, Kodama F, et al. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol. 2012;7(9):1385–1393. doi:10.2215/CJN.08110811.
   PubMed Web of Science ®Google Scholar
• Farzamikia N, Baradaran B, Mostafavi S, et al. Podocyte-derived microparticles in IgA nephropathy. Biomed Pharmacother. 2021;141:111891. doi: 10.1016/j.biopha.2021.111891.
   PubMed Web of Science ®Google Scholar
• Morita M, Sakaguchi H. A quantitative study of glomerular basement membrane changes in IgA nephropathy. J Pathol. 1988;154(1):7–18. doi:10.1002/path.1711540103.
   PubMed Web of Science ®Google Scholar
• Berthoux FC, Laurent B, Alamartine E, Diab N. New subgroup of primary IgA nephritis with thin glomerular basement membrane (GBM): syndrome or association. Nephrol Dial Transplant. 1996;11(3):558–559. doi:10.1093/oxfordjournals.ndt.a027334.
   PubMed Web of Science ®Google Scholar
• Danilewicz M, Wagrowska-Danilewicz M. Glomerular basement membrane thickness in primary diffuse IgA nephropathy: ultrastructural morphometric analysis. Int Urol Nephrol. 1998;30(4):513–519. doi:10.1007/BF02550234.
   PubMedGoogle Scholar
• Yoshikawa N, Yoshiara S, Yoshiya K, Matsuo T, Okada S. Lysis of the glomerular basement membrane in children with IgA nephropathy and Henoch-schonlein nephritis. J Pathol. 1986;150(2):119–126. doi:10.1002/path.1711500206.
   PubMed Web of Science ®Google Scholar
• Sinniah R, Churg J. Effect of IgA deposits on the glomerular mesangium in Berger’s disease. Ultrastruct Pathol. 1983;4(1):9–22. doi:10.3109/01913128309140568.
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Kida H, Abe T, Takeda S, Katagiri M, Hattori N. Significance of IgA deposits on the glomerular capillary walls in IgA nephropathy. Am J Kidney Dis. 1987;9(5):404–409. doi:10.1016/s0272-6386(87)80143-9.
   PubMed Web of Science ®Google Scholar
• Lee SM, Rao VM, Franklin WA, et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13(4):314–322. doi:10.1016/s0046-8177(82)80221-9.
   PubMed Web of Science ®Google Scholar
• Kitamura M, Obata Y, Ota Y, Abe H, et al. Significance of subepithelial deposits in patients diagnosed with IgA nephropathy. PLoS One. 2019;14(2):e0211812. doi: 10.1371/journal.pone.0211812.
   PubMed Web of Science ®Google Scholar
• Lee HS, Choi Y, Lee JS, Yu BH, Koh HI. Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data. Kidney Int. 1989;35(3):880–886. doi:10.1038/ki.1989.68.
   PubMed Web of Science ®Google Scholar